In addition to our results demonstrating that JMJD3/UTX and p300 inhibition may provide therapeutic benefit to patients with T-ALL, two additional manuscripts present preclinical evidence in support of this claim (Ntziachristos et al., 2014; Xia et al., 2019). The gene discussed is KDM6A; the disease is acute lymphoblastic leukemia.